Publications

The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Continuous Vutrisiran Reduces Cardiovascular Events and Hospitalizations in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B One-Year Open Label Extension

Publication Details

Journal of Cardiac Failure

October 2026

Access Here

Author(s)

Sarah A M Cuddy¹, Jan M Griffin², W H Wilson Tang³, Olivier Lairez⁴, Caroline Morbach⁵, Francesco Cappelli⁶, Farooq H Sheikh⁷, Hua Zheng⁸, Benjamin W Lee⁸, Alisa R Kosheleff⁸, Ronald M Witteles⁹

Affiliations

¹Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; ²Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA; ³Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA; ⁴Department of Cardiology, HealthAge Institute, University Hospital of Toulouse, Toulouse, France; ⁵Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Center and Department of Medicine I, University Hospital Würzburg, Würzburg, Germany; ⁶Tuscan Regional Amyloidosis Centre, Department of Clinical and Experimental Medicine, Careggi University Hospital, Florence, Italy; ⁷Medstar Heart and Vascular Institute, Georgetown University School of Medicine, Washington, DC, USA; ⁸Alnylam Pharmaceuticals, Cambridge, MA, USA; ⁹Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA

Abstract

Background

Vutrisiran significantly reduced the risk of all-cause mortality and recurrent cardiovascular (CV) events vs placebo in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in the phase 3 HELIOS-B study (NCT04153149). Here, we report the long-term impact of vutrisiran on hospitalizations and urgent heart failure (HF) visits from the ongoing HELIOS-B open-label extension (OLE).

Methods

In HELIOS-B, patients received vutrisiran 25 mg or placebo every 3 months over a 33–36-month double-blind period, followed by a 24-month OLE continuing with vutrisiran (continuous treatment), or if previously receiving placebo, initiating vutrisiran (delayed treatment). Hospitalizations and urgent HF visits were analyzed through 48 months (12 months of the OLE) in the overall and monotherapy (not receiving tafamidis at baseline) populations, and the baseline tafamidis subgroup.

Results

Of 654 participants, 466 entered the OLE. Continuous vutrisiran reduced the risk of all-cause hospitalizations vs delayed treatment in the overall population (relative rate ratio [RRR] 0.71, 95% confidence interval [CI] 0.62–0.82, P<0.001) and the monotherapy population (RRR 0.60, 95% CI 0.50–0.72, P<0.001). Continuous vutrisiran also significantly reduced the risk of CV hospitalizations, HF hospitalizations, and non-CV hospitalizations vs delayed vutrisiran in the overall and monotherapy populations, and urgent HF visits in the overall population and baseline tafamidis subgroup.

Conclusions

Continuous vutrisiran reduced the risk of CV events and hospitalizations relative to patients originally randomized to placebo in HELIOS-B. Many treatment effects were of greater magnitude at 48 months vs 36 months with continuous vutrisiran, highlighting the benefits of earlier diagnosis and treatment.